Use of positron emission tomography for staging, preoperative response assessment and posttherapeutic evaluation in children with Wilms tumour

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 35, Issue 9, 2008, Pages 1642-1650

  Misch, Daniel ^a   Steffen, Ingo G ^a   Schönberger, Stefan ^b   Voelker, Thomas ^a   Furth, Christian ^a   Stöver, Brigitte ^a   Hautzel, Hubertus ^b   Henze, Günter ^a   Amthauer, Holger ^a   Denecke, Timm ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Paediatric oncology; PET; Preoperative response assessment; Staging; Wilms tumour

Indexed keywords

FLUORODEOXYGLUCOSE;

ADOLESCENT; ADULT; ARTICLE; CANCER RISK; CANCER STAGING; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MALE; NEPHROBLASTOMA; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; TUMOR DIFFERENTIATION;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; INFANT; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RECURRENCE; WILMS TUMOR;

EID: 50449097025     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-008-0819-9     Document Type: Article

References (31)

1. J Lemerle PA Voûte MF Tournade JF Delemarre B Jereb L Ahstrohm 1976 Preoperative versus postoperative radiotherapy, single versus multiple courses of Actinomycin D, in the treatment of Wilms tumor. Preliminary results of a controlled clinical trial conducted by the International Society of Pediatric Oncology (SIOP) Cancer 38 647 654
2. A Weirich R Ludwig N Graf U Abel I Leuschner GM Vujanic 2004 Survival in nephroblastoma treated according to the trial and study SIOP-9/GPOH with respect to relapse and morbidity Ann Oncol 15 808 820
3. J De Kraker J Lemerle PA Voute JM Zucker MF Tournade M Carli 1990 Wilm's tumor with pulmonary metastases at diagnosis: the significance of primary chemotherapy. International Society of Pediatric Oncology Nephroblastoma Trial and Study Committee J Clin Oncol 8 1187 1190
4. H Reinhard O Semler D Burger U Bode M Flentje U Göbel 2004 Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral nonmetastatic Wilms Tumor Klin Padiatr 216 132 140
5. A Weirich I Leuschner D Harms GM Vujanic J Tröger U Abel 2001 Clinical impact of histologic subtypes in localized non-anaplastic nephroblastoma treated according to the trial and study SIOP 9/GPOH Ann Oncol 12 311 319
6. JS Dome T Liu M Krasin L Lott P Shearer NC Daw 2002 Improved survival for patients with recurrent Wilms tumor: the experience at St. Jude Children's Research Hospital J Pediatr Hematol Oncol 24 192 198
7. ML Metzger JS Dome 2007 Current therapy for Wilms' tumor Oncologist 10 815 826
8. C Mitchell K Pritchard-Jones R Shannon C Hutton S Stevens D Machin 2006 For the United Kingdom Cancer Study Group. Immediate nephrectomy versus preoperative chemotherapy in the management of non-metastatic Wilms' tumour: results of a randomised trial (UKW3) by the UK Children's Cancer Study Group Eur J Cancer 42 2554 2562
9. L Boccon-Gibod A Rey B Sandstedt J Delemarre D Harms G Vujanic 2000 Complete necrosis induced by preoperative chemotherapy in Wilms tumor as an indicator of low risk: report of the international society of paediatric oncology (SIOP) nephroblastoma trial and study 9 Med Pediatr Oncol 34 183 190
10. J De Kraker N Graf H van Tinteren F Pein B Sandstedt M Godzinski 2004 Reduction of postoperative chemotherapy in children with stage I intermediate-risk and anaplastic Wilms' tumour (SIOP 93-01 trial): a randomised controlled trial Lancet 364 1229 1235
11. I Ora H van Tinteren C Bergeron J de Kraker 2007 SIOP Nephroblastoma Study Committee. Progression of localised Wilms' tumour during preoperative chemotherapy is an independent prognostic factor: a report from the SIOP 93-01 nephroblastoma trial and study Eur J Cancer 43 131 136
12. P Grundy N Breslow DM Green K Sharples A Evans GJ D'Angio 1989 Prognostic factors for children with recurrent Wilms' tumor: results from the Second and Third National Wilms' Tumor Study J Clin Oncol 7 638 647
13. JS Miser MF Tournade 1995 The management of relapsed Wilms tumor Hematol Oncol Clin North Am 9 1287 1302
14. CW Carrico MD Cohen JM Zerin R Weetman 1997 Wilms tumor imaging: patient costs and protocol compliance Radiology 204 627 633
15. H Amthauer C Furth T Denecke P Hundsdoerfer T Voelker K Seeger 2005 FDG-PET in 10 children with non-Hodgkin's lymphoma: initial experience in staging and follow-up Klin Padiatr 217 327 333
16. C Furth H Amthauer T Denecke J Ruf G Henze M Gutberlet 2006 Impact of whole-body MRI and FDG-PET on staging and assessment of therapy response in a patient with Ewing sarcoma Pediatr Blood Cancer 47 607 611
17. C Furth T Denecke I Steffen J Ruf T Voelker D Misch 2006 Correlative imaging strategies implementing CT, MRI, and PET for staging of childhood Hodgkin disease J Pediatr Hematol Oncol 28 501 512
18. C Franzius J Sciuk C Brinkschmidt H Jürgens O Schober 2000 Evaluation of chemotherapy response in primary bone tumors with F-18 FDG positron emission tomography compared with histologically assessed tumor necrosis Clin Nucl Med 25 874 881
19. C Franzius J Sciuk HE Daldrup-Link H Jürgens O Schober 2000 FDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy Eur J Nucl Med 27 1305 1311
20. T Györke T Zajic A Lange O Schäfer E Moser E Mako 2006 Impact of FDG PET for staging of Ewing sarcomas and primitive neuroectodermal tumours Nucl Med Commun 27 17 24
21. D Korholz R Kluge L Wickmann W Hirsch H Lüders I Lotz 2003 Importance of F18-fluorodeoxy-d-2-glucose positron emission tomography (FDG-PET) for staging and therapy control of Hodgkin's lymphoma in childhood and adolescence-consequences for the GPOH-HD 2003 protocol Onkologie 26 489 493
22. T Völker T Denecke I Steffen D Misch S Schönberger M Plotkin 2007 Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial J Clin Oncol 25 5435 5441
23. DS Hawkins JG Rajendran EU Conrad JD Bruckner JF Eary 2002 Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-d-glucose positron emission tomography Cancer 94 3277 3284
24. DS Hawkins SM Schuetze JE Butrynski JG Rajendran CB Vernon EU Conrad 2005 [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors J Clin Oncol 23 8828 8834
25. M Hernandez-Pampaloni A Takalkar JQ Yu H Zhuang A Alavi 2006 F-18 FDG-PET imaging and correlation with CT in staging and follow-up of pediatric lymphomas Pediatr Radiol 36 524 531
26. GR Johnson H Zhuang J Khan SB Chiang A Alavi 2003 Roles of positron emission tomography with fluorine-18-deoxyglucose in the detection of local recurrent and distant metastatic sarcoma Clin Nucl Med 28 815 820
27. AL Folpe RH Lyles JT Sprouse EU Conrad JF Eary 2000 (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma Clin Cancer Res 6 1279 1287
28. JD Lucas MJ O'Doherty BF Cronin PK Marsden MA Lodge PH McKee 1999 Prospective evaluation of soft tissue masses and sarcomas using fluorodeoxyglucose positron emission tomography Br J Surg 86 550 556
29. M Schulte D Brecht-Krauss B Heymer A Guhlmann E Hartwig MR Sarkar 2000 Grading of tumors and tumorlike lesions of bone: evaluation by FDG PET J Nucl Med 41 1695 1701
30. BL Shulkin E Chang PJ Strouse DA Bloom RJ Hutchinson 1997 PET FDG studies of Wilms tumors J Pediatr Hematol Oncol 19 334 338
31. C Franzius HE Daldrup-Link J Sciuk EJ Rummeny S Bielack H Jürgens 2001 FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: comparison with spiral CT Ann Oncol 12 479 486